Last updated on September 2018

Dose-finding Study to Assess the Efficacy Safety and Tolerability of Tobramycin Inhalation Powder in Patients With Non-Cystic Fibrosis Bronchiectasis and Pulmonary P. Aeruginosa Infection


Brief description of study

The purpose of this study is to support the selection of a safe and tolerable tobramycin inhalation powder (TIP) dose, and regimen that exhibits effective bacterial reduction of P. aeruginosa in non-cystic fibrosis bronchiectasis (BE) patients with P. aeruginosa colonization.

Detailed Study Description

This is a blinded, randomized, dose- and regimen finding trial where active TIP doses or placebo is given in addition to the local standard care.

Clinical Study Identifier: NCT02712983

Contact Investigators or Research Sites near you

Start Over

Novartis Pharmaceuticals

Novartis Investigative Site
Barakaldo, Spain
  Connect »